menu
    • menu
    [{"orgOrder":0,"company":"48Hour Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"48Hour Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"48Hour Discovery \/ Oranomed","highestDevelopmentStatusID":"3","companyTruncated":"48Hour Discovery \/ Oranomed"},{"orgOrder":0,"company":"48Hour Discovery","sponsor":"Alberta Cancer Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"48Hour Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"48Hour Discovery \/ Alberta Cancer Foundation","highestDevelopmentStatusID":"3","companyTruncated":"48Hour Discovery \/ Alberta Cancer Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by 48Hour Discovery

    Menu

    48Hour Discovery

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            48Hour Discovery

                            Canada arrow
                            CPhI India
                            Not Confirmed

                            48Hour Discovery

                            Canada arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Oranomed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Orano Med and 48Hour to Develop Novel Peptide Receptor Radionuclide for Targeted Cancer

                            Details : Partnership aims to harness the potent properties of lead-212 (212Pb), a rare alpha-emitting radioisotope, in conjunction with 48Hour Discovery’s innovative peptide discovery technology and expertise.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 06, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Oranomed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            48Hour Discovery

                            Canada arrow
                            CPhI India
                            Not Confirmed

                            48Hour Discovery

                            Canada arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Alberta Cancer Foundation

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Alberta Cancer Foundation Announces Initial Investment for Early-Stage Cancer Research

                            Details : 48Hour Discovery funds radiopeptide-based theranostics for cancer treatment with improved precision.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Alberta Cancer Foundation

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth